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OBJECTIVE—We aimed to verify the association between diabe-
tes and the risk of dementia, Alzheimer’s disease, and vascular
dementia in twins and to explore whether genetic and early-life
environmental factors could contribute to this association.
RESEARCH DESIGN AND METHODS—This study included
13,693 twin individuals aged 65 years. Dementia was diagnosed
according to DSM-IV (Diagnostic Manual of Mental Disorders,
4th ed.) criteria. Information on diabetes was collected from the
inpatient registry and self- or informant-reported history of
diabetes. Data were analyzed following two strategies: 1) un-
matched case-control analysis for all participants using general-
ized estimating equation (GEE) models and 2) cotwin matched
case-control analysis for dementia-discordant twin pairs using
conditional logistic regression.
RESULTS—Of all participants, 467 were diagnosed with
dementia, including 292 with Alzheimer’s disease and 105 with
vascular dementia, and an additional 170 were diagnosed with
questionable dementia. Diabetes was present in 1,396 sub-
jects. In GEE models, diabetes was associated with adjusted
odds ratios (ORs) (95% CI) of 1.89 (1.51–2.38) for dementia,
1.69 (1.16–2.36) for Alzheimer’s disease, and 2.17 (1.36–3.47)
for vascular dementia. Compared with late-life diabetes (onset
age 65 years), the risk effect of mid-life diabetes (onset age
65 years) on dementia was stronger. Conditional logistic
analysis of 210 dementia-discordant twin pairs led to ORs of
2.41 (1.05–5.51) and 0.68 (0.30–1.53) for dementia related to
mid- and late-life diabetes, respectively.
CONCLUSIONS—Diabetes increases the risk of Alzheimer dis-
ease and vascular dementia. The risk is stronger when diabetes
occurs at mid-life than in late life. Genetic and early-life environ-
mental factors might contribute to the late-life diabetes–demen-
tia association but could not account for the mid-life diabetes–
dementia association. Diabetes 58:71–77, 2009
P
opulation-based longitudinal studies (1–12) have
shown that the risk of dementia in general is
increased in people with diabetes. Even pre-
diabetes has been associated with an increased
risk of dementia and Alzheimer disease (13). Although
diabetes may be linked to dementia through several bio-
logically plausible pathways (14), our understanding of the
mechanisms for such an association is still limited. Both
dementia and diabetes are complex age- and lifestyle-
related disorders. In addition to strong inﬂuence of envi-
ronmental elements, genetic components also play a part
in both Alzheimer’s disease and diabetes (15,16). Epidemi-
ological and clinical studies (11,17–19) have reported that
environmental factors acting in early life, such as birth
weight and childhood socioeconomic situation, are also
involved in the development of diabetes as well as demen-
tia. Evidence from genetic and epidemiological studies
(20,21) has indicated that genetic and environmental fac-
tors may interact to affect the association between diabe-
tes and dementia during the life course.
The recent upsurge of interest in applying a life-course
approach to chronic disease epidemiology and the hypoth-
esis of “developmental origins of adult disease” prompt
renewed attention to twin studies. Twins provide naturally
matched pairs, in which confounding effects of a large
number of potentially causal factors (e.g., genetics and
childhood environment) may be removed when compari-
sons are made between twins. Because twins are generally
reared together, they share their early-life environment.
Twin studies involving a life-course approach may help to
identify genetic inﬂuences and timing of environmental
inﬂuences on the relationship between age-related disor-
ders. In the current study, we sought to 1) verify the
association between diabetes and risk of dementia and its
main subtypes in twins, 2) examine whether the effect of
diabetes on dementia risk varies according to age of
diabetes onset, and 3) explore whether genetic and early-
life familial environmental factors could explain this asso-
ciation using data from the population-based Swedish twin
cohort.
RESEARCH DESIGN AND METHODS
Participants were members of the nationwide Swedish Twin Registry (22). In
1998–2001, all living twins in the registry who were born in 1935 and earlier
(aged 65 years) were invited to participate in a study concerning dementia
known as HARMONY (23). In brief, a total of 20,206 individuals in the Swedish
Twin Registry were eligible for screening. Of these, 5,771 were not reached by
a telephone, 712 could be reached but were not able to undertake the
interview, and 30 failed to complete the cognitive screening test, leading to
13,693 subjects with complete cognitive test data. Of these, a total of 1,939
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DIABETES, VOL. 58, JANUARY 2009 71individuals were invited to the clinical phase, including participants who were
screened as positive for cognitive dysfunction, subjects who were with
suspected dementia, or demented twin’s partner and normal control subjects.
Clinical diagnoses were available for 1,357 individuals. The participation rates
were 71.4% for the screening phase and 70.0% for the clinical phase (Fig. 1).
Informed consent was required from all participants during the telephone
interview and again in the clinical phase. The data collection procedures were
reviewed and approved by the Swedish Data Inspection Board, Stockholm,
Sweden; the Regional Ethics Committee at Karolinska Institutet, Stockholm;
and the institutional review board of the University of Southern California.
Diagnosis of dementia and its major subtypes. A two-step procedure was
used in the diagnosis of dementia. The ﬁrst step was cognitive screening
through a telephone interview using the validated TELE questionnaire for the
twins (24,25) and the Blessed Dementia Rating Scale for the informants (26).
The TELE and Blessed Dementia Rating Scale were combined into an ordinal
scale with scores ranging from 0 (cognitive intact) to 3 (cognitive dysfunction)
(24). The second step was a full clinical workup that entailed a visit by an
assessment team composed of a nurse and a physician. The assessment team
made an initial diagnosis based on a protocol that followed the Consortium to
Establish a Registry for Alzheimer’s Disease and included physical and
neurological examination, a review of medical history, informant interview,
and a neuropsychological assessment. The neuropsychological battery in-
cluded the Mini-Mental State Examination; the Consortium to Establish a
Registry for Alzheimer’s Disease word list immediate and delayed recall,
verbal ﬂuency, block design, ﬁgure coping, judgment, information, symbol-
digit, and prospective memory; as well as the Memory in Reality test. These
preliminary diagnoses were reviewed by a diagnostic board consisting of a
neurologist and a neuropsychologist. Clinical diagnoses of dementia followed
DSM-IV criteria (27). The case subjects completely fulﬁlling the DSM-IV
criteria were diagnosed as having “dementia,” in contrast with a category of
“questionable dementia,” which was used for individuals who did not fulﬁll
one of the ﬁrst three DSM-IV diagnostic criteria but did exhibit either cognitive
impairment or functional disability. Participants were ﬁrst classiﬁed as
demented, questionable, or nondemented and then given a differential diag-
nosis for dementia subtype for demented subjects (23). Differential diagnoses
were made according to the National Institute of Neurological and Commu-
nicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders
Association criteria for Alzheimer’s disease (28) and the National Institute of
Neurological Disorders and Stroke-Association Internationale pour la Recher-
che et l’Enseignement en Neurosciences criteria for vascular dementia (29).
More details of the clinical examination and diagnostic procedure have been
reported previously (24). The age of dementia onset was estimated by the
assessment team based on information that was obtained from a detailed
informant interview. Age at onset was deﬁned as the age when deﬁnite and
enduring symptoms of dementia ﬁrst appeared (30).
Covariates and identiﬁcation of diabetes. For 13,693 individuals who
participated in the screening phase, information concerning demographic
factors, education, health status and behavior, common diseases, use of
medications, height, and weight was obtained during the telephone interview.
For twins who had completed surveys by the Swedish Twin Registry in 1961,
1963, and 1967 for the older cohort and in 1973 for the younger cohort,
information on height and weight is available. Information on history of
vascular disorders (hypertension, heart disease, and stroke) was derived from
the inpatient registry system. Each record in the system included up to eight
discharge diagnoses according to the ICD-7 through 1968. ICD-8 was used by
the register system until 1986; since 1987 the ICD-9 has been used. Medical
conditions derived from the inpatient register database included hypertension
(ICD-7 codes 444–447, ICD-8 codes 400–404, and ICD-9 codes 401–405),
ischemic heart disease (ICD-7 codes 420–421, ICD-8 and -9 codes 410–414),
cardiac dysrhythmia, heart failure or other myocardial insufﬁciency (ICD-7
codes 433 and 434, ICD-8 and -9 codes 427 and 428), and stroke (ICD-7 codes
330–334, ICD-8 and -9 codes 430–438). Vascular diseases including hyperten-
sion, heart disease (ischemic heart disease, cardiac heart disease, cardiac
dysrhythmia, and heart failure), and stroke were ascertained based on the
information from self- or informant-report and the inpatient registry. Survival
status from screening phase to October 2004 was obtained from the Cause of
Death Register.
Diabetes was detected by integrating information from inpatient registry
(ICD-7 codes 260, ICD-8 and -9 codes 250) and self- and informant-reported
history of diabetes. The age of diabetes onset was estimated according to the
earliest recorded date of diabetes either in the inpatient registry or the date of
diabetes onset reported by probands or informants. To address the potential
modifying role of age at the time of exposure on dementia risk, we distin-
guished mid-life (aged 65 years) and late life (aged 65 years) diabetes (31).
Information on the age of diabetes onset was missing in 71 (5.1%) patients.
The date of telephone interview was used as approximate onset date for these
patients in the analyses, although it may lead to underestimation of the
association of diabetes duration with dementia risk.
Statistical analysis. The characteristics of participants with dementia,
questionable dementia, and nondementia were compared using 
2 tests for
categorical variables, one-way ANOVA for continuous variables with normal
distribution, and Mann-Whitney test for continuous variables with nonnormal
distribution. To verify whether the association between diabetes and demen-
tia differed depending on diagnostic certainty, multinomial logistic regression
was used to estimate the odds ratios (ORs) and 95% CIs of dementia and
questionable dementia separately in relation to diabetes.
Two analytical strategies were applied: 1) unmatched case-control analy-
ses using generalized estimating equation (GEE) models, which are concep-
tually equivalent to logistic regression for the analysis of classical case-control
design but control for the clustering of twins within a pair; and 2) dementia-
discordant cotwin matched case-control analyses using conditional logistic
regression models (Fig. 2). The latter strategy is more informative than using
unrelated case-control samples, and it allows matching for unmeasured
familial factors, which could be related to genetic background or early life
environment. Case and control subjects are comparable with respect to
genetic and early-life environmental history (such as childhood socioeco-
nomic status) (32). If the association found in GEE analyses becomes
attenuated in cotwin matched case-control analyses, genetic factors or
familial environments or both are likely to play a role in the association. If
strength of the association further decreases when only monozygotic twin
The HARMONY Study population 
14,435 (71.4%) Reached by telephone 
5,771 Dropouts 
712 Not interviewable 
467 Dementia  170 Questionable 
20,206 Eligible twins aged ≥65   
13,056 non-demented
13,693 Participants with complete cognitive test data 
13,723 Participated in screening tests
Screening phase 
(1998-2001) 
Clinical phase 
30 Missing co
(1998-2002) 
1,357 Clinical diagnosis available 
1,939 Invited to the clinical phase
gnitive test data 
FIG. 1. Flowchart of the study population in the HARMONY study.
28 Type 1 diabetes
13,693 Twin individuals
Multinomial Logistic Regression 
637  Dementia+Questionable 
13,028 Controls 
210 Dementia discordant pairs 
Conditional Logistic Regression  GEE model 
467 Dementia 
170 Questionable 
13,028 Controls
Strategy I 
Conventional case-control 
Strategy II 
Matched case-control
47 Both demented   
4,017 Both non-demented 
5,117 Single twins 
4,274 Pairs 
13,665 Twin individuals
FIG. 2. Two analytical strategies for the HARMONY study.
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signiﬁcant association remains when using cotwin matched pairs, the inﬂu-
ences of genetic or early environmental factors on the association are likely to
be marginal (22). We hypothesized that diabetes would be a signiﬁcant risk
factor for dementia in a classical case-control analysis, whereas in the
matched-pair analysis, by controlling for genetic, maternal (maternal nutrition
status and disease) (17,18), and environmental factors shared by twins, we
would ﬁnd an attenuated association between diabetes and dementia. Logistic
regression was used to test the difference in ORs from the GEE model and
conditional logistic regression by examining the difference of diabetes among
unmatched versus cotwin control subjects (23).
Age, sex, education, zygotic status, vascular factors (i.e., heart disease
including ischemic heart disease, cardiac dysrhythmia and heart failure,
stroke, and hypertension), and BMI were considered as potential confounders
in all models. Education was missing in 155 subjects. The expectation
maximization imputation method was used to replace the missing information
based on Little’s test for missing completely at random. The statistical
analyses were performed using SAS statistical software version 9.1 (SAS
institute, Cary, NC) and SPSS 15.0 (SPSS, Chicago, IL)
RESULTS
Among 13,693 participants, 467 (3.4%) received a diagnosis
of dementia including 292 with Alzheimer’s disease and
105 with vascular dementia, and an additional 170 (1.4%)
were diagnosed with questionable dementia. The preva-
lence of dementia was 3.9% in female and 2.7% in male
subjects (
2  17.5, P  0.001). The prevalence of demen-
tia in this Swedish twin cohort was comparable with
several major epidemiological studies of dementia preva-
lence in Europe and the U.S. (23). The estimated mean age
of dementia onset was 76.8 years.
Of 13,693 participants, 1,288 were self-reported and 99
were informant-reported as having diabetes at the screen-
ing phase, which covered 276 (88.2%) of 313 subjects
recorded as having diabetes in the inpatient registry. In
total, diabetes was identiﬁed in 1,424 subjects (10.4%),
including 28 type 1 diabetic patients (1.9% of all diabetic
patients). The prevalence of type 2 diabetes (1,396) was
9.8% in female and 11.2% in male subjects (
2  6.83, P 
0.009). The mean age of type 2 diabetes onset was 63.8
years.
Table 1 shows the characteristics of the study partici-
pants by dementia status. Compared with nondemented
participants, subjects with dementia or questionable de-
mentia were older, had a lower level of education and BMI
at the time of assessment (using categorical variable as
covariate in following analyses), had a higher proportion
of monozygotic and same-sex dizygotic zygosity, and were
more likely to have type 2 diabetes, stroke, and heart
disease. Data on current BMI were missing in 1,614 twins.
The prevalence of dementia and questionable dementia
was 4.7% in participants with BMI available and 4.4% in
participants with missing BMI (
2  0.26, P  0.601). In
the subsequent analyses, 28 patients with type 1 diabetes
were excluded.
Characteristics of the 1,396 patients with type 2 diabetes
are reported in Table 2. Compared with people with
late-life diabetes, participants with mid-life diabetes had
TABLE 1
Characteristics of the study participants (n  13,693) by dementia diagnosis
No
dementia
Questionable
dementia Dementia P value
n 13,056 170 467
Age (years) 73.1  6.4 79.8  6.8 81.5  6.6 0.001
Female sex 7,281 (55.8) 84 (49.4) 302 (64.5) 0.001
Education (years)* 8.6  3.0 7.9  2.8 7.4  2.4 0.001
Zygotic status
Monozygotic 3,070 (23.5) 47 (27.7) 138 (29.5)
Same sex dizygotic 5,404 (41.4) 72 (42.4) 209 (44.8)
Oppsite sex dizygotic 4,351 (33.3) 49 (28.8) 104 (22.3)
Indeterminate 231 (1.8) 2 (1.2) 16 (3.4) 0.001
Type 2 diabetes 1,257 (9.6) 32 (18.8) 107 (22.9) 0.001
Type 1 diabetes 28 (0.2) — — —
Stroke 937 (7.2) 52 (30.6) 142 (30.4) 0.001
Heart disease 1,540 (11.8) 72 (42.4) 326 (69.8) 0.001
Hypertension 4,334 (33.2) 57 (33.5) 166 (35.6) 0.05
BMI (kg/m
2) 25.1  3.7 24.4  3.6 23.9  4.7 0.001
25 6,024 (46.1) 257 (55.0) 97 (57.1)
25–29.99 4,531 (34.7) 114 (24.4) 55 (32.4)
30 958 (7.3) 34 (7.3) 9 (5.3)
Missing 1,543 (11.8) 62 (13.3) 9 (5.3) 0.001
Data are n (%) or means  SD. *A total of 155 subjects had missing value of education.
TABLE 2
Clinical characteristics of patients with type 2 diabetes by onset
age of diabetes (n  1,396)
All
patients
Onset age
65 years
Onset age
65 years P
n 1,396 643 753
Age (years) 74.4  6.6 71.5  5.4 77.0  6.5 0.001
Female 751 (52.6) 307 (41.9) 426 (58.1) 0.001
Onset age 64.2  12.2 54.6  10.2 72.4  6.2 0.001
Duration (years)
(median) 8.0 14.0 3.0 0.001
Modality of
treatment
Oral drugs 582 (41.7) 264 (41.4) 318 (42.2)
Insulin 100 (7.3) 61 (9.5) 39 (5.2)
Oral drugs
and insulin 291 (21.3) 201 (31.3) 90 (12.0)
Diet 272 (19.1) 93 (14.0) 179 (23.6)
Missing 151 (10.8) 24 (3.7) 127 (16.9) 0.001
Hypertension 748 (53.6) 362 (56.3) 386 (51.3) 0.060
Heart disease 341 (24.2) 92 (14.3) 246 (32.7) 0.001
Stroke 233 (16.7) 86 (13.4) 147 (19.5) 0.002
Data are n (%) or means  SD, unless otherwise indicated.
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treatment with insulin. In the multinomial logistic analysis
including the whole study population, diabetes was signif-
icantly associated with an increased risk of both dementia
and questionable dementia. As the diabetes-related ORs
were similar for dementia and questionable dementia,
these two categories were combined as outcome of de-
mentia in subsequent analyses (Table 3).
Table 4 shows the basic- and multiadjusted ORs and 95%
CIs of dementia, Alzheimer’s disease, and vascular demen-
tia in association with diabetes derived from the GEE
models. Diabetes was signiﬁcantly related to increased
risk of dementia, Alzheimer’s disease, and vascular demen-
tia. The risk tended to be higher for vascular dementia
than for Alzheimer’s disease. We also examined the effect
of mid-life and late-life diabetes on dementia risk. Com-
pared with patients with late-life diabetes, patients with
mid-life diabetes appeared to be at a higher risk for
dementia. The effect of mid-life diabetes on dementia risk
remained statistically signiﬁcant even after additional ad-
justment for diabetes duration (OR 2.07 [95% CI 1.12–
3.68]).
All participants included 4,274 twin pairs and 5,117
single twins. Of 4,274 twin pairs, 4,071 were pairs in which
both were nondemented and 47 were pairs in which both
were demented, leaving 210 pairs discordant for dementia
status. In the cotwin matched case-control analyses in-
cluding both monozygotic and dizygotic pairs, the associ-
ation between mid-life diabetes and dementia risk
remained signiﬁcant after adjustment for sex, education,
stroke, heart disease, hypertension, and BMI at age 65
years, but the association with late-life diabetes largely
diminished (Table 5). Of 210 dementia-discordant pairs, 46
pairs were monozygotic and 161 pairs were dizygotic. The
multiadjusted ORs of dementia related to diabetes were
1.06 (95% CI 0.48–2.34) in dizygotic pairs and 1.87 (0.30–
11.79) in monozygotic pairs.
In GEE models, mid- and late-life diabetes were signif-
icantly associated with 176% (OR 2.76 [95% CI 1.97–3.87])
and 63% (1.63 [1.23–2.16]) increased risk for dementia,
respectively (Table 4). In the conditional logistic regres-
sion analyses, the point estimate of ORs for dementia
related to mid-life diabetes dropped only slightly and was
still signiﬁcant (2.41 [1.05–5.51]), but the OR related to
late-life diabetes was largely attenuated and no longer
statistically signiﬁcant (0.68 [0.30–1.53]) (Table 5). The
attenuation of the regressing coefﬁcients between un-
paired and paired analyses in twins suggests that factors
that are common to twins in a pair contribute to the
observed association in whole cohort. The ORs from GEE
models based on all participants and those from condi-
tional logistic models based on dementia-discordant pairs
for the association of dementia with late-life diabetes were
statistically signiﬁcantly different (1.76 [1.08–2.88]; P 
0.02), but no difference was detected for the mid-life
diabetes–dementia association (1.04 [0.55–1.99]; P  0.89).
The comparison of the results from the whole cohort and
matched pairs indicated that the inﬂuences of genetic or
family environmental factors on the association between
mid-life diabetes and dementia might be small, but they
play a role in the late-life diabetes–dementia association.
Among 13,693 participants, 2,633 died between the
screening phase and 2004. In the GEE model, type 2
diabetes was related to an elevated risk of death with a
multiadjusted OR of 2.15 (95% CI 1.87–2.47). We repeated
the analysis using mean age of diabetes onset for 71
diabetic patients with missing age at diabetes onset, which
produced the results that were much the same as those
from the initial analysis. Further, combination of subjects
with questionable dementia and nondemented subjects as
control subjects did not alter the initial results. Finally, the
analyses were repeated in 8,534 participants with mid-life
BMI available, for which information on weight and height
during the age of 40–65 years was taken from the Swedish
TABLE 3
Adjusted OR (95% CI) of dementia and questionable dementia related to diabetes: results from multinomial logistic regression
Dementia
status Subjects (n)
Diabetic case
subjects (n)
Basic-adjusted
OR (95% CI)*
Multiadjusted
OR (95% CI)†
No dementia 13,028 1,257 1.00 (reference) 1.00 (reference)
Questionable 170 32 2.56 (2.02–1.34) 1.99 (1.58–2.64)
Dementia 467 107 2.00 (1.34–2.96) 1.76 (1.17–2.65)
*Adjusted for age, sex, and education. †Adjusted for age, sex, education, zygosity status, stroke, heart disease, hypertension, and BMI.
TABLE 4
Adjusted OR (95% CI) of dementia, Alzheimer’s disease, and vascular dementia related to diabetes and separately to diabetes with
onset before and after age 65 years: results from GEE models
Subjects (n) All dementia Alzheimer’s disease Vascular dementia
Diabetes status
No 12,296 498; 1.00 (reference);
1.00 (reference)
236; 1.00 (reference);
1.00 (reference)
74; 1.00 (reference);
1.00 (reference)
Yes 1,396 139; 2.45 (1.97–3.03)*;
1.89 (1.51–2.38)†
56; 2.03 (1.47–2.80)*;
1.69 (1.16–2.36)†
31; 3.60 (2.33–5.57)*;
2.17 (1.36–3.47)†
Age of diabetes onset
65 years 643 48; 2.95 (2.14–4.08)*;
2.76 (1.97–3.87)†
16; 2.32 (1.37–3.94)*;
2.25 (1.29–3.92)†
12; 4.94 (2.61–9.35)*;
3.94 (1.90–8.15)†
65 years 753 91; 2.12 (1.64–2.75)*;
1.63 (1.23–2.16)†
40; 1.88 (1.29–2.74)*;
1.56 (1.05–2.32)†
19; 2.90 (1.70–4.94)*;
1.62 (0.92–2.80)†
Data are n; OR (95% CI) or OR (95% CI). *Adjusted for age, sex, and education. †Adjusted for age, sex, education, stroke, heart disease,
hypertension, and BMI.
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adjusting for mid-life BMI (data not shown).
DISCUSSION
In this large-scale population-based twin study, diabetes is
independently associated with an increased risk of demen-
tia, Alzheimer’s disease, and vascular dementia. The risk
effect is stronger in people with mid-life diabetes than in
those with late-life diabetes. Findings from cotwin
matched case-control analyses suggest that unmeasured
familial factors (genetic factors and early life environ-
ments) might contribute to the association between late-
life diabetes and dementia but could not account for the
association of mid-life diabetes with dementia.
Diabetes is a risk factor for cognitive impairment and
dementia, as reported in numerous population-based stud-
ies, but it remains in debate whether this concerns only
vascular dementia or also Alzheimer’s disease. Some pro-
spective studies did ﬁnd an association between diabetes
and increased risk of Alzheimer’s disease (1,2,5,9,11,12,
33), while others did not (3,4,6,10). We found that diabetes
is associated with moderately increased risk of dementia,
Alzheimer’s disease, and vascular dementia in Swedish
twins. The risk tends to be stronger for vascular dementia.
These results are in agreement with ﬁndings from the
Honolulu-Asia Aging Study (5), which reported an associ-
ation between diabetes and increased risk of dementia,
Alzheimer’s disease, and vascular dementia. We also found
that patients with mid-life diabetes had greater dementia
risk than those with late-life diabetes. Recent reports (34)
showed that long-term diabetes has a stronger risk effect
for the development of cognitive impairment and demen-
tia. However, in our study the association between mid-life
diabetes and dementia was still signiﬁcant after adjust-
ment for diabetes duration, suggesting that age at expo-
sure to diabetes may also be relevant for the development
of dementia.
Neuroimaging studies have recently demonstrated that
people with type 2 diabetes had moderately elevated risk
for lacunes, hippocampal atrophy, and deep white matter
lesions, which support the notion that the increased risk of
cognitive decline and dementia in people with diabetes is
probably due to dual pathological processes involving
both cerebrovascular damage and neurodegenerative
changes (35). In addition to microvascular and macrovas-
cular disease, there are other pathophysiological mecha-
nisms through which diabetes could increase the risk of
dementia, including glycemia, insulin resistance, oxidative
stress, advanced glycation end products, and inﬂammatory
cytokines (20,36). Hyperinsulinemia is suggested to ex-
plain the increased risk of Alzheimer’s disease in diabetic
patients, as the effect of high levels of insulin on dementia
risk is independent of diabetes and blood glucose (37).
These pathways may act separately or interactively, but
which of these mechanisms are clinically relevant is
unclear. In addition, the different mechanisms may inter-
act during the long prodromal phases of both diabetes and
dementia (38).
In cotwin control analyses, the risk effect of mid-life
diabetes on dementia remained signiﬁcant, but the associ-
ation between late-life diabetes and dementia risk was
largely diminished. Thus, the association between late-life
diabetes and dementia may be attributed to genetic and
early environmental factors (such as maternal nutrition
status and childhood socioeconomic situation), although
similar exposures at mid-life and late life could also have
occurred. These ﬁndings suggest that the association
observed in the unmatched case-control analysis between
late-life diabetes and dementia is more likely to be endog-
enous. Our ﬁndings support recent evidence that the
molecular defects associated with the development of
diabetes also contribute to an increased risk of all types of
dementia (39). Genome-wide association studies have
shown that the insulin-degrading enzyme (IDE) gene links
to both late-onset Alzheimer’s disease and type 2 diabetes
(40). IDE has been demonstrated to degrade insulin and
-amyloid and to inhibit islet amyloid polypeptide (a
protein coexpressed and secreted with insulin by -cells)
oligomer formation and cytotoxicity (41). There may be
shared predisposition for developing islet amyloid in pa-
tients with diabetes and brain amyloid in those with
Alzheimer’s disease. A population-based clinicopathologi-
cal study (42) has shown the possible link between neu-
rodegenerative processes that lead to loss of cortical brain
cells in Alzheimer’s disease and the loss of -cells in type
2 diabetes. Furthermore, there is now abundant evidence
that early-life growth and development has an effect on
risk of disease in adult life (43). Several studies have
observed the relationship between low birth weight and
increased risk of diabetes (44). In addition, childhood low
socioeconomic status may also contribute to the risk of
both diabetes (19) and dementia (45). Thus, the link
between diabetes and dementia is probably determined by
the complex interplay of genetic and environmental expo-
sures throughout the life course.
In contrast to late-life diabetes, mid-life diabetes was
associated with an increased risk of dementia even when
controlling for genetic and familial factors, suggesting that
mid-life diabetes–dementia association might be exoge-
nous and is more likely attributable to adulthood environ-
TABLE 5
Cotwin matched case-control analyses on the association of diabetes with dementia by age of diabetes onset: results from conditional
logistic regression models
All twin pairs
(n  210)
Diabetes onset at
midlife (n  100)
Diabetes onset in
latelife (n  110)
Demented twin
(no diabetes; diabetes)
Demented twin
(no diabetes; diabetes)
Demented twin
(no diabetes; diabetes)
Nondemented cotwin
No diabetes 139; 37 63; 22 76; 15
Diabetes 23; 11 9; 6 14; 5
Basic-adjusted OR (95% CI)* 1.67 (0.96–2.92) 2.51 (1.10–5.72) 1.32 (0.66–2.65)
Multiadjusted OR (95% CI)† 1.15 (0.55–2.38) 2.41 (1.05–5.51) 0.68 (0.30–1.53)
*Adjusted for sex and education. †Adjusted for sex, education, stroke, heart disease, hypertension, and BMI.
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smoking, and social activities as well as glycemic control
in patients with diabetes) (21). Our results indicate that
genetic and unmeasured early-life environmental factors
are likely to play a role in the association of late-life
diabetes with dementia but could not explain mid-life
diabetes in association with dementia, which implicated
the involvement of adulthood environments in the devel-
opment of mid-life diabetes–dementia association and
highlighted the need to maintain a healthy lifestyle during
adulthood in order to reduce the risk of dementia late in
life.
Obesity is related to inﬂammation and insulin resis-
tance, and the lifespan-dependent relation of obesity with
dementia has been reported (46). In our study, information
on weight and height were based on self- or informant
report, and BMI as a covariate in the analyses may lead to
residual confounding. However, all our analyses showed
that BMI did not substantially affect the diabetes-dementia
association, suggesting that the confounding due to BMI
on the diabetes-dementia association, if it exists, is likely
to be minimal.
Some limitations of the study should be mentioned.
First, the use of prevalent dementia cases may have
introduced some confounding effect due to differential
survival among case subjects. In this study, the mean age
of diabetes onset was much younger than the mean age of
dementia onset. The temporality of the given association is
clear. In addition, diabetes is associated with an elevated
mortality in our study as reported previously (47), which
would probably lead to an underestimation of the strength
of association between diabetes and dementia risk. Sec-
ond, we identiﬁed patients with diabetes based on self-
and informant-reported information and on inpatient med-
ical history. Information on blood glucose concentration
was not available. Because diabetes is commonly (30%)
undiagnosed in elderly people (48), in this study a substan-
tial proportion of the subjects with diabetes might have
been erroneously assigned to the nondiabetic group,
which would also lead to an underestimation of the risk
attributable to diabetes. Third, both sets of inﬂuences are
anonymous; thus, we are unable to infer which genes
might be involved or which environmental factors might
be important. Fourth, information from informants was
used for participants who could not provide information
about history of diseases due to impaired cognition (7.0%).
However, the bias of using reports from an informant has
been previously found to be minimal (49). Finally, both
diabetes and dementia (especially Alzheimer’s disease) are
genetically inﬂuenced disorders with substantial concor-
dance in twins (15,50). Thus, the matched pairs could be
regarded as “overmatched,” as twin pairs are similar on
many aspects, such as genetic susceptibility and lifestyle.
Nevertheless, the comparison of the results from the
cohort as a whole with the matched pairs provides impor-
tant information about the potential role of genetic and
familial inﬂuences in the associations from the cohort
analyses. Furthermore, as the discordant pairs included
both monozygotic and dizygotic twins, genetic effects
were not perfectly controlled for.
In conclusion, our results show that diabetes increases
the risk of Alzheimer’s disease and vascular dementia in
the Swedish twins. The risk effect is stronger when diabe-
tes occurs at mid-life than in late life. These ﬁndings add to
the growing evidence of a link between diabetes, vascular
damage, and neurodegenerative changes in the brain.
Genetic and early-life environmental factors might contrib-
ute to the association between late-life diabetes and
dementia, but adulthood environments might be responsi-
ble for mid-life diabetes–dementia association. These ﬁnd-
ings suggest that diabetes-dementia association may
develop across a lifespan. Further studies are required to
reveal which early life and adulthood environmental fac-
tors as well as genes might be involved for the diabetes-
dementia association.
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